Ranibizumab therapy for neovascular age-related macular degeneration

N Engl J Med. 2010 Oct 21;363(17):1648-55. doi: 10.1056/NEJMct1000495.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Choroidal Neovascularization
  • Humans
  • Injections, Intraocular / adverse effects
  • Male
  • Practice Guidelines as Topic
  • Ranibizumab
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Wet Macular Degeneration / drug therapy*
  • Wet Macular Degeneration / physiopathology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Ranibizumab